JP2008536488A - 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物 - Google Patents
遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物 Download PDFInfo
- Publication number
- JP2008536488A JP2008536488A JP2008502127A JP2008502127A JP2008536488A JP 2008536488 A JP2008536488 A JP 2008536488A JP 2008502127 A JP2008502127 A JP 2008502127A JP 2008502127 A JP2008502127 A JP 2008502127A JP 2008536488 A JP2008536488 A JP 2008536488A
- Authority
- JP
- Japan
- Prior art keywords
- probe set
- affymetrix
- gene
- expression
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 226
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 154
- 201000011510 cancer Diseases 0.000 title claims abstract description 99
- 230000004083 survival effect Effects 0.000 title claims abstract description 82
- 206010060862 Prostate cancer Diseases 0.000 title claims description 121
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 114
- 238000000034 method Methods 0.000 title claims description 71
- 230000034994 death Effects 0.000 title description 9
- 239000000203 mixture Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 189
- 210000000130 stem cell Anatomy 0.000 claims abstract description 74
- 201000010099 disease Diseases 0.000 claims abstract description 68
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 68
- 101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 claims abstract description 25
- 102100034836 Proliferation marker protein Ki-67 Human genes 0.000 claims abstract description 24
- 101000938676 Homo sapiens Liver carboxylesterase 1 Proteins 0.000 claims abstract description 21
- 102100031347 Metallothionein-2 Human genes 0.000 claims abstract description 21
- 102100036817 Ankyrin-3 Human genes 0.000 claims abstract description 20
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims abstract description 20
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims abstract description 20
- 101000928342 Homo sapiens Ankyrin-3 Proteins 0.000 claims abstract description 20
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 claims abstract description 19
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 claims abstract description 19
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 claims abstract description 17
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 claims abstract description 17
- 102100027849 Homeobox protein GBX-2 Human genes 0.000 claims abstract description 12
- 101000859754 Homo sapiens Homeobox protein GBX-2 Proteins 0.000 claims abstract description 12
- 102100037964 E3 ubiquitin-protein ligase RING2 Human genes 0.000 claims abstract description 11
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 claims abstract description 11
- 101000807524 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 22 Proteins 0.000 claims abstract description 11
- 108010027310 Host Cell Factor C1 Proteins 0.000 claims abstract description 11
- 102000018726 Host Cell Factor C1 Human genes 0.000 claims abstract description 11
- 102100037184 Ubiquitin carboxyl-terminal hydrolase 22 Human genes 0.000 claims abstract description 11
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 claims abstract description 10
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 claims abstract description 10
- 206010066901 Treatment failure Diseases 0.000 claims abstract description 9
- 239000000523 sample Substances 0.000 claims description 126
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 104
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 52
- 230000001394 metastastic effect Effects 0.000 claims description 45
- 208000023958 prostate neoplasm Diseases 0.000 claims description 35
- 238000005259 measurement Methods 0.000 claims description 27
- 206010006187 Breast cancer Diseases 0.000 claims description 22
- 208000026310 Breast neoplasm Diseases 0.000 claims description 22
- 239000002299 complementary DNA Substances 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 8
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 208000000172 Medulloblastoma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000011471 prostatectomy Methods 0.000 claims description 5
- 238000002271 resection Methods 0.000 claims description 5
- 210000001625 seminal vesicle Anatomy 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 201000010653 vesiculitis Diseases 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 206010027406 Mesothelioma Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 230000009545 invasion Effects 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 75
- 206010027476 Metastases Diseases 0.000 abstract description 36
- 230000009401 metastasis Effects 0.000 abstract description 23
- 230000037361 pathway Effects 0.000 abstract description 21
- 238000010195 expression analysis Methods 0.000 abstract description 17
- 230000004913 activation Effects 0.000 abstract description 10
- 230000002068 genetic effect Effects 0.000 abstract description 8
- 238000007429 general method Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 108
- 101150000874 11 gene Proteins 0.000 description 104
- 101100058548 Felis catus BMI1 gene Proteins 0.000 description 62
- 238000004393 prognosis Methods 0.000 description 52
- 238000004458 analytical method Methods 0.000 description 47
- 238000010837 poor prognosis Methods 0.000 description 36
- 230000000306 recurrent effect Effects 0.000 description 34
- 238000012360 testing method Methods 0.000 description 31
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 26
- 230000001105 regulatory effect Effects 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000003169 central nervous system Anatomy 0.000 description 17
- 230000003902 lesion Effects 0.000 description 17
- 206010061819 Disease recurrence Diseases 0.000 description 15
- 238000002493 microarray Methods 0.000 description 14
- 238000011830 transgenic mouse model Methods 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 238000010208 microarray analysis Methods 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 210000002307 prostate Anatomy 0.000 description 11
- 230000003211 malignant effect Effects 0.000 description 10
- 238000011472 radical prostatectomy Methods 0.000 description 10
- 238000010200 validation analysis Methods 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 9
- 239000002853 nucleic acid probe Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 210000001178 neural stem cell Anatomy 0.000 description 8
- 201000001514 prostate carcinoma Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 7
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 7
- 102100038358 Prostate-specific antigen Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 238000013517 stratification Methods 0.000 description 7
- 101150082072 14 gene Proteins 0.000 description 6
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000030279 gene silencing Effects 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 201000005249 lung adenocarcinoma Diseases 0.000 description 6
- 208000037819 metastatic cancer Diseases 0.000 description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 238000011223 gene expression profiling Methods 0.000 description 5
- 230000004547 gene signature Effects 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 5
- 238000000491 multivariate analysis Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 4
- 108010022429 Polycomb-Group Proteins Proteins 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000010841 mRNA extraction Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000000064 prostate epithelial cell Anatomy 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 231100000588 tumorigenic Toxicity 0.000 description 4
- 230000000381 tumorigenic effect Effects 0.000 description 4
- 101150029857 23 gene Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 102000012425 Polycomb-Group Proteins Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 108091008053 gene clusters Proteins 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 238000012775 microarray technology Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000002018 overexpression Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000611 regression analysis Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 101150076401 16 gene Proteins 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- 208000014061 Extranodal Extension Diseases 0.000 description 2
- 102000004989 Hepsin Human genes 0.000 description 2
- 108090001101 Hepsin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 108010048992 Transcription Factor 4 Proteins 0.000 description 2
- 102100023489 Transcription factor 4 Human genes 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000025164 anoikis Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000005741 malignant process Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000007473 univariate analysis Methods 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101100137547 Arabidopsis thaliana PRF3 gene Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 101150090105 Ezh2 gene Proteins 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- -1 KTTC2 Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
- 101100444898 Mus musculus Egr1 gene Proteins 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 238000001190 Q-PCR Methods 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 206010073104 Tubular breast carcinoma Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101100137778 Zea mays PRO5 gene Proteins 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000011256 aggressive treatment Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 101150097231 eg gene Proteins 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000002696 invasive tubular breast carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66301405P | 2005-03-16 | 2005-03-16 | |
| PCT/US2006/009870 WO2006110264A2 (en) | 2005-03-16 | 2006-03-16 | Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009061926A Division JP2009131278A (ja) | 2005-03-16 | 2009-03-13 | 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008536488A true JP2008536488A (ja) | 2008-09-11 |
| JP2008536488A5 JP2008536488A5 (enExample) | 2009-05-07 |
Family
ID=37087482
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008502127A Pending JP2008536488A (ja) | 2005-03-16 | 2006-03-16 | 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物 |
| JP2009061926A Pending JP2009131278A (ja) | 2005-03-16 | 2009-03-13 | 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009061926A Pending JP2009131278A (ja) | 2005-03-16 | 2009-03-13 | 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8349555B2 (enExample) |
| EP (1) | EP1874471A4 (enExample) |
| JP (2) | JP2008536488A (enExample) |
| AU (1) | AU2006234897A1 (enExample) |
| WO (1) | WO2006110264A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010131006A (ja) * | 2008-10-31 | 2010-06-17 | Dna Chip Research Inc | 神経膠腫予後予測方法、およびそれに用いるキット |
| JP2012527679A (ja) * | 2009-05-20 | 2012-11-08 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 分子署名に基づくバイオマーカ |
| CN108474040A (zh) * | 2015-10-09 | 2018-08-31 | 夸登特健康公司 | 使用无细胞dna的基于群体的治疗推荐 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130122504A1 (en) * | 2011-11-14 | 2013-05-16 | Lars Dyrskjot Andersen | Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer |
| JP5150855B2 (ja) * | 2005-07-29 | 2013-02-27 | オンコセラピー・サイエンス株式会社 | Ｃｄｃａ１−ｋｎｔｃ２複合体を標的とするスクリーニングおよびｎｓｃｌｃの治療方法 |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| BRPI0711011A2 (pt) | 2006-05-18 | 2011-08-23 | Molecular Profiling Inst Inc | método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença |
| WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| DE102007044919A1 (de) * | 2007-09-19 | 2009-04-02 | Hefter, Harald, Prof. Dr. med. Dr. rer. nat. | Verfahren zur Bestimmung von sekundärem Therapieversagen |
| JP5407018B2 (ja) * | 2007-12-28 | 2014-02-05 | 国立大学法人名古屋大学 | 肺腺癌患者の術後再発を予測するための方法及び組成物 |
| EP2806054A1 (en) * | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| US8227202B2 (en) | 2008-07-10 | 2012-07-24 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| EP3075864A1 (en) * | 2008-10-14 | 2016-10-05 | Caris MPI, Inc. | Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type |
| EP3181705A1 (en) * | 2008-11-12 | 2017-06-21 | Caris Life Sciences Switzerland Holdings GmbH | Methods and systems of using exosomes for determining phenotypes |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| MX338883B (es) * | 2010-07-27 | 2016-05-04 | Genomic Health Inc | Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata. |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| CA2856981A1 (en) * | 2011-11-23 | 2013-06-27 | Uti Limited Partnership | Expression signature for staging and prognosis of prostate, breast and leukemia cancers |
| WO2013090620A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| SG11201404390WA (en) | 2012-01-31 | 2014-08-28 | Genomic Health Inc | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| ES2945036T3 (es) * | 2012-08-16 | 2023-06-28 | Veracyte Sd Inc | Pronóstico del cáncer de próstata mediante biomarcadores |
| WO2014028907A1 (en) | 2012-08-16 | 2014-02-20 | The Trustees Of Columbia University In The City Of New York | Diagnostic markers of indolent prostate cancer |
| KR101993716B1 (ko) * | 2012-09-28 | 2019-06-27 | 삼성전자주식회사 | 카테고리별 진단 모델을 이용한 병변 진단 장치 및 방법 |
| US9687290B2 (en) | 2012-10-02 | 2017-06-27 | Covidien Lp | Energy-based medical devices |
| TWI658049B (zh) * | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| US20160040212A1 (en) * | 2013-03-15 | 2016-02-11 | The Broad Institute, Inc. | Methods for the Detection of DNA-RNA Proximity in Vivo |
| CN110444289A (zh) * | 2013-06-28 | 2019-11-12 | 南托米克斯有限责任公司 | 用于诊断检测的识别的途径分析 |
| ES2923942T3 (es) | 2013-11-06 | 2022-10-03 | Us Health | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| GB201322034D0 (en) | 2013-12-12 | 2014-01-29 | Almac Diagnostics Ltd | Prostate cancer classification |
| FR3017955B1 (fr) * | 2014-02-27 | 2018-04-06 | Assistance Publique - Hopitaux De Paris | Biomarqueurs diagnostics de la cardiomyopathie du peripartum |
| WO2016036878A1 (en) * | 2014-09-02 | 2016-03-10 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
| TWI582240B (zh) * | 2015-05-19 | 2017-05-11 | 鄭鴻鈞 | 以基因體預後評估試劑組預測乳癌患者局部區域復發風險及放射治療有效性的方法、用途及裝置 |
| WO2017184861A1 (en) | 2016-04-20 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Evaluation of mantle cell lymphoma and methods related thereto |
| JP6963009B2 (ja) | 2016-05-19 | 2021-11-05 | オンコスカー エルエルシーOncoscar Llc | 臨床的に難治性の悪性腫瘍の診断及び治療標的化の方法 |
| US11414708B2 (en) | 2016-08-24 | 2022-08-16 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| AU2018210695B2 (en) | 2017-01-20 | 2024-07-18 | The University Of British Columbia | Molecular subtyping, prognosis, and treatment of bladder cancer |
| US11873532B2 (en) | 2017-03-09 | 2024-01-16 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| WO2018205035A1 (en) | 2017-05-12 | 2018-11-15 | Genomedx Biosciences, Inc | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
| EP3715476A1 (en) * | 2019-03-29 | 2020-09-30 | Centre National De La Recherche Scientifique | Prognosis method of cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004025258A2 (en) * | 2002-09-10 | 2004-03-25 | Sydney Kimmel Cancer Center | Gene segregation and biological sample classification methods |
| US20050208500A1 (en) * | 2003-03-04 | 2005-09-22 | Erlander Mark G | Signatures of ER status in breast cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6218122B1 (en) * | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
| US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
| NL1014106C2 (nl) | 2000-01-18 | 2001-07-20 | Univ Amsterdam | Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit. |
| DK1410011T3 (da) * | 2001-06-18 | 2011-07-18 | Netherlands Cancer Inst | Diagnose og prognose for brystcancerpatienter |
| AU2002358279A1 (en) | 2001-12-21 | 2003-07-30 | Arcturus Engineering, Inc. | Biomarkers for breast cancer |
| US8065093B2 (en) * | 2004-10-06 | 2011-11-22 | Agency For Science, Technology, And Research | Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers |
| WO2006060646A2 (en) * | 2004-12-03 | 2006-06-08 | Board Of Regents, The University Of Texas System | Cell microarray for profiling of cellular phenotypes and gene function |
| US20090098538A1 (en) * | 2006-03-31 | 2009-04-16 | Glinsky Gennadi V | Prognostic and diagnostic method for disease therapy |
| CA2648021A1 (en) * | 2006-03-31 | 2007-10-11 | Ordway Research Institute, Inc. | Prognostic and diagnostic method for cancer therapy |
-
2006
- 2006-03-16 WO PCT/US2006/009870 patent/WO2006110264A2/en not_active Ceased
- 2006-03-16 US US11/908,775 patent/US8349555B2/en not_active Expired - Fee Related
- 2006-03-16 AU AU2006234897A patent/AU2006234897A1/en not_active Abandoned
- 2006-03-16 JP JP2008502127A patent/JP2008536488A/ja active Pending
- 2006-03-16 EP EP06748441A patent/EP1874471A4/en not_active Withdrawn
-
2009
- 2009-03-13 JP JP2009061926A patent/JP2009131278A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004025258A2 (en) * | 2002-09-10 | 2004-03-25 | Sydney Kimmel Cancer Center | Gene segregation and biological sample classification methods |
| US20050208500A1 (en) * | 2003-03-04 | 2005-09-22 | Erlander Mark G | Signatures of ER status in breast cancer |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010131006A (ja) * | 2008-10-31 | 2010-06-17 | Dna Chip Research Inc | 神経膠腫予後予測方法、およびそれに用いるキット |
| JP2012527679A (ja) * | 2009-05-20 | 2012-11-08 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 分子署名に基づくバイオマーカ |
| US11348662B2 (en) | 2009-05-20 | 2022-05-31 | Koninklijke Philips N.V. | Biomarkers based on sets of molecular signatures |
| CN108474040A (zh) * | 2015-10-09 | 2018-08-31 | 夸登特健康公司 | 使用无细胞dna的基于群体的治疗推荐 |
| JP2018537754A (ja) * | 2015-10-09 | 2018-12-20 | ガーダント ヘルス， インコーポレイテッド | 無細胞ｄｎａを使用する集団ベースの処置レコメンダ |
| JP6991134B2 (ja) | 2015-10-09 | 2022-01-12 | ガーダント ヘルス， インコーポレイテッド | 無細胞ｄｎａを使用する集団ベースの処置レコメンダ |
| JP2024167909A (ja) * | 2015-10-09 | 2024-12-04 | ガーダント ヘルス， インコーポレイテッド | 無細胞ｄｎａを使用する集団ベースの処置レコメンダ |
Also Published As
| Publication number | Publication date |
|---|---|
| US20090233279A1 (en) | 2009-09-17 |
| EP1874471A4 (en) | 2008-12-10 |
| WO2006110264A2 (en) | 2006-10-19 |
| AU2006234897A1 (en) | 2006-10-19 |
| JP2009131278A (ja) | 2009-06-18 |
| EP1874471A2 (en) | 2008-01-09 |
| WO2006110264A3 (en) | 2007-03-01 |
| US8349555B2 (en) | 2013-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008536488A (ja) | 遺伝子発現署名を使用する、癌による死亡および前立腺癌生存率を予測するための方法および組成物 | |
| ES2525382T3 (es) | Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino | |
| KR101530689B1 (ko) | 직장결장암용 예후 예측 | |
| TWI540320B (zh) | 肺癌及大腸直腸癌之分子標記 | |
| JP6049739B2 (ja) | 前立腺癌の分類のためのマーカー遺伝子 | |
| CA2646254A1 (en) | Propagation of primary cells | |
| MX2014009283A (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| US20090192045A1 (en) | Molecular staging of stage ii and iii colon cancer and prognosis | |
| AU2008203226B2 (en) | Colorectal cancer prognostics | |
| JP2004329211A (ja) | 結腸直腸癌の予後 | |
| US20160222461A1 (en) | Methods and kits for diagnosing the prognosis of cancer patients | |
| US20150344962A1 (en) | Methods for evaluating breast cancer prognosis | |
| CN103562404A (zh) | 预测肝癌预后的组合物或试剂盒以及预测肝癌预后的方法 | |
| CA3049844A1 (en) | Algorithms and methods for assessing late clinical endpoints in prostate cancer | |
| CN106967719A (zh) | 一种长链非编码rna作为前列腺癌分子标志物的应用 | |
| CA2475769C (en) | Colorectal cancer prognostics | |
| CN102361990A (zh) | 通过监测两种基因的表达的乳腺癌患者的预后 | |
| CN111315897B (zh) | 用于黑素瘤检测的方法 | |
| EP2633068A1 (en) | Metagene expression signature for prognosis of breast cancer patients | |
| JP5963748B2 (ja) | 中枢神経原発悪性リンパ腫患者の予後予測方法、キット及び使用 | |
| WO2018187673A1 (en) | Mirna signature expression in cancer | |
| JP2011211989A (ja) | 悪性神経膠腫患者の予後予測方法 | |
| WO2019195935A1 (en) | Methods for monitoring and treating prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090313 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090313 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111019 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120308 |